The smart speaker market continues to boom in this AI-driven world owing to the utilitarian nature of virtual assistant integrated speakers, which make daily life easier by handling small but inevitable tasks smartly and efficiently.Moreover, the adoption rate of smart speakers has rapidly increased amid the ongoing coronavirus pandemic due to shelter-in-place restrictions, which have led several house-arrested people throughout the world to tap on news content, important information related to the COVID-19 pandemic, music content and other entertainment stuff just via voice commands.Additionally, the growing proliferation of virtual assistants and improving AI skills are aiding these speakers to become more advanced with each passing day, which is further increasing their adoption rate in this fast-paced world.Further, increasing penetration rate of Internet usage and the emergence of 5G technology are continuously aiding growth of the market for these speakers. Also, rising number of smart homes across the world is encouraging.All the above-mentioned factors are indicating that the smart speaker space holds an upside potential and hence, companies such as Alphabet’s GOOGL Google, Amazon AMZN, Apple AAPL, Samsung, Alibaba BABA, Baidu BIDU and Xiaomi, to name a few, are making every effort to capitalize on the prospects of this particular market on the back of their robust smart speaker offerings and improving AI skills.According to a report from MarketsandMarkets, the global smart speaker market is anticipated to reach $7.1 billion in 2020 and $15.6 billion by 2025, at a CAGR of 17.1% between 2020 and 2025.
Immense growth opportunities in the smart speaker market are inciting two major players, Google and Amazon, to make further advances into it.Google’s latest launch of Nest Audio, which is the successor of Google Home, is a testament to this fact. The built-in 19mm tweeter and 75mm mid-woofer are expected to aid the adoption rate of this speaker.Notably, the move bodes well for the company’s growing efforts toward expanding the smart speaker portfolio. In addition to Nest Audio, Nest Mini, which is also included in Google’s smart speaker offerings, is witnessing solid adoption owing to its affordable price.Further, the company’s improving AI techniques are benefiting Google Assistant skills. This remains the key catalyst behind the company’s strengthening position in the smart speaker market.Currently, Google’s parent company, Alphabet carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Amazon is riding on robust features of Echo devices, which poise it well to reap benefits from this particular space. Further, its strong focus on expanding the Echo family of smart speakers remains noteworthy. The recent launch of the all-new Echo, Echo Dot, Echo Dot with clock, Echo Dot Kids Edition and Echo Show 10 is a major positive. Notably, all these new devices hold the Climate Pledge Friendly badge.The incorporation of Amazon’s first-generation AZ1 Neural Edge processor, which is known for accelerating machine learning applications, in the new Echo and Echo Show 10 is expected to deliver enhanced user experience. Further, Echo Dot’s built-in 1.6-inch, front-firing speaker, Echo Dot with clock’s simple LED display and Echo Dot Kids Edition’s strong parental controls are likely to drive Amazon’s customer momentum.Moreover, improving Alexa skills and expanding global footprint are tailwinds for the company, which currently carries a Zacks Rank #3.
Although Apple is experiencing low sales of the smart speaker HomePod due to its late entry into the market, the company’s concerted efforts to grab a significant market share remain a positive.Apple is gearing up to launch the low-priced version of HomePod, which is expected to provide it with a strong foothold in the smart speaker market.Moreover, superior music quality in HomePod gives it an edge over other speakers in the market. Also, strong presence of HomePod in the premium market is noteworthy.Additionally, this Zacks Rank #3 company’s loyal customer base, brand loyalty and expanding global footprint are tailwinds.
The smart speaker market of China is exploding on the back of constant technical advancements in the country. Given this upbeat scenario, Alibaba and Baidu are constantly putting in efforts to advance their smart speakers, namely Xiaodu and Tmall Genie.Alibaba’s recent plans to invest $1.4 billion for developing the next generation of technology, which will be centred around the Tmall Genie smart speaker, remains a major positive.Further, this Zacks Rank #3 company’s partnership with Starbucks — which allows China-based customers to order Starbucks’ beverages and food via Tmall Genie — is contributing well to the adoption rate of the smart speaker.Meanwhile, Baidu — carrying a Zacks Rank #3 at present — is gaining from the robust AI platform called DuerOS, which is likely to continue aiding the adoption rate of smart speakers.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.Click Here, See It Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN) : Free Stock Analysis Report Apple Inc. (AAPL) : Free Stock Analysis Report Baidu, Inc. (BIDU) : Free Stock Analysis Report Alphabet Inc. (GOOGL) : Free Stock Analysis Report Alibaba Group Holding Limited (BABA) : Free Stock Analysis Report To read this article on Zacks.com click here.
The carmaker took the wraps off a major operational and management shake-up on its CEO’s first day in the role.
He predicted the mortgage crisis, oil’s fall from $100 to $40, and the March stock market bottom. Now he’s found our next big crisis and opportunity.
PepsiCo’s CFO Hugh Johnston talks with Yahoo Finance about the company’s key new product launch and latest earnings report.
Political debate swirls around the Trump tax returns. Trump reportedly paid $750 in his first year in the White House. How much did some predecessors pay?
The traditional mix of stocks and bonds won’t work in a world of near-zero interest rates. It’s time to ponder the alternatives.
Our technology will match you with the best lenders at super low rates. Trusted by over 15 million. Save thousands each year. 2.39% APR
Former coal CEO Robert E. Murray, who has fought federal regulations on the industry, has filed an application with the U.S. Department of Labor for black lung benefits, according to a published report. West Virginia Public Broadcasting and Ohio Valley ReSource report the former head of Murray Energy said on the form that he is still board chairman of the company but can no longer serve as president and CEO due to his health.
The Dubai-based construction company that helped build the world’s tallest building and other engineering marvels in the United Arab Emirates announced Thursday it would enter liquidation, the final step in a long collapse from the country’s economic crisis a decade ago hastened by the coronavirus pandemic. Arabtec Holding PJSC made the announcement after emails circulated Wednesday among developers suggesting the firm’s end had come. Despite trying to claw its way out of the chaos left by Dubai’s 2009 financial crisis, the firm ended last year with hundreds of millions of dollars in debt and losses.
Chinese electric vehicle maker Nio Inc. (NYSE: NIO) on Friday said September was a record month for deliveries.What Happened: The Shanghai-based company reported delivering 4,708 units in the month, a growth of 133.2% year-over-year.Nio said it sold 3,210 ES6, 1,482 ES8, and 16 EC6 model vehicles.Overall, deliveries increased 154.3% in the quarter ending Sept. 30 over the similar quarter previous year at 12,206, exceeding the company’s previously-shared guidance.The company said this brought its total combined sale of the three models to-date at 58,288, including 26,375 this year alone.Why It Matters: Deutsche Bank Securities analyst Edison Yu earlier this week said he expected Nio to post record deliveries in the third and fourth quarters this year, especially on the back of the EC6 sports utility vehicle.Nio began deliveries for the EC6 SUV in late September.Local rival Li Auto Inc. (NASDAQ: AT THE) reported 3,504 electric vehicle deliveries in September on Friday, as well. Overall, the number increased 31.31% quarter-over-quarter at 8,660.Facing intense local competition, Tesla Inc. (NASDAQ: TSLA) this week slashed prices of its standard and long-range Shanghai-made Model 3 electric vehicles.Price Action: Nio shares traded 2.4% lower at $21.24 in the pre-market session Friday.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Tesla’s China-Made Electric Vehicle Registrations Plunged 24% In July(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Leading Gut Health Expert & frequent guest of Dr. Oz and Good Morning America is begging we all change this one thing
The much-hyped Nikola Badger electric pickup looks like an endangered species. It is absent from the electric truck startup’s road map of milestones, and a delayed manufacturing deal with General Motors Company (NYSE: GM) points to its demise before a physical prototype is ever revealed.The Badger was not in Nikola Corp. (NASDAQ: NKLA) business plan a year ago. And it isn’t there now. Founder Trevor Milton used it as a buzz-building tool for the company following the reveal of rival Tesla Inc. (NASDAQ: TSLA) Cybertruck, a polarizing design that the electric truck leader plans to build at a new plant in Austin, Texas.”A lot of people didn’t like the look of the Cybertruck, including me,” Nikola CEO Mark Russell said on the company’s earnings call on Aug. 4. “I think it looks like a doorstop. But they got lots of reservations for it. So Trevor just released the concept that we had for the pickup truck.”Nikola put the Badger image on the company website where 89,000 people expressed interest. “That’s when we got serious about it and said, ‘I think the world wants us to build this darn thing,’ but it wasn’t in the plan before,” Russell said. “So we said, ‘Hey, if we’re going to do it, we’re going to need a partner.”Mum’s the word Nikola began taking Badger deposits of up to $5,000 on June 29. It promised the truck, priced between $60,000 and $90,000, would be revealed at NikolaWorld 2020 in December in Phoenix. Citing Arizona rules against large gatherings during the pandemic, Nikola indefinitely postponed the event on Wednesday.A spokeswoman declined Thursday to say how many deposits the company received for the Badger or how much money was collected.In an interview with FreightWaves on Wednesday, Russell declined to answer when asked whether Milton’s association with the Badger hurt its prospects. He said only that the Badger was part of the ongoing GM discussions he could not characterize.The competition for electric pickup trucks is huge. In addition to the Cybertruck, established automakers GM and Ford Motor Company (NYSE: F) and startups Rivian and Lordstown Motors plan entries. Nikola does not have a distribution or sales network for the Badger, which would remain a Nikola product even with GM as its contract manufacturer. It also needs money to pay GM for each truck. That is $700 million based on 50,000 trucks, according to the U.S. Securities and Exchange Commission (SEC) filing on the GM-Nikola deal. All of Nikola’s current cash is dedicated to construction of its $600 million assembly plant in Coolidge, Arizona.”As we execute on the roadmap we’ve laid out, that should allow us to go back to the market and get additional capital,” Russell told FreightWaves on Wednesday.The GM negotiations People close to the situation told FreightWaves that Milton was “hell bent” on getting a manufacturing partner for the Badger. It became part of negotiations with GM about supplying batteries and fuel cells for Nikola’s Class 7-8 heavy-duty trucks in North America.When Nikola and GM announced a deal Sept. 8 under which GM would get an 11% ownership in Nikola in exchange for using GM’s battery-elect truck platform, the two sides said they expected the deal to close before Wednesday.Those talks are continuing after Nikola’s stock cratered following a short seller’s report Sept. 10 that alleged years of fraud and misrepresentations by Milton. Ten days later, Milton resigned as executive chairman and left the company.The $2 billion GM was to receive was based on nearly 48 million new shares priced at $41.93. Nikola shares fell into the mid-teens last week. They are recovering since the company issued a lengthy press release Wednesday laying out milestones the company plans to achieve through 2023. Nikola has about 400 million outstanding shares. Diluting existing shareholders by issuing new shares is a trap that electric delivery van maker Workhorse Group (NASDAQ: WKHS) found itself in after listing on the NASDAQ. Still Workhorse shares are rading near its record high as it is finally producing vans.Will GM get more of Nikola or walk away? Even at a price of $23.81 at 2 p.m. EDT on Thursday, the value of the deal for GM is well below the agreement. Either side can walk away if it does not close by Dec. 3. It is possible that GM could seek more shares and a larger stake in Nikola, though the original deal accounts for share price movement.GM has no cash in the Nikola deal, so it has little downside. It negotiated to get 80% of zero emission vehicle (ZEV) credits that Badger sales generate. Those credits help offset pollution penalties generated by GM’s large trucks and SUVs.”This arrangement initially seemed like a pretty good deal for both parties,” said Mike Ramsey, a Gartner Inc. vice president who follows autos and mobility. “But as it has become more complicated with recent revelations, GM is more likely to seek more ironclad certainty that they will not be embarrassed or have some other unexpected downside going forward.”Batteries and fuel cells The other part of the Nikola-GM deal — supplying batteries and fuel cells to Nikola’s heavy-duty trucks — got less attention. But it might mean more to GM as it provides entry into the heavy-duty trucking space where the company does not compete.”I think the fuel cell stuff is probably the bigger incremental value to GM,” Sam Abuelsamid, principal analyst at Guidehouse Insights, told FreightWaves. “This is their first real customer for them. So I think that’s clearly got to be the priority.”GM would be happy to soak up assembly capacity with the Badger and capture the ZEV credits, he said. One downside for GM is that Nikola has the “cool kid” image that an old line manufacturer like GM lacks. “Even though it’s the exact same hardware, people that want to buy an electric truck might be more interested in buying from a Nikola than a GM,” Abuelsamid said. “From Mark Russell’s standpoint, it probably would be wise to drop the Badger and focus on the trucks.”Related articles: Nikola battles back: Electric truck startup seeks to calm investorsGM deal with Nikola delayed beyond anticipated closing dateNikola begins Badger electric pickup marketing pushClick for more FreightWaves articles by Alan Adler.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * GM Deal With Nikola Delayed Beyond Anticipated Close * Nikola’s Hunt For Hydrogen Station Partner Stalled – WSJ(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Tesla Inc (NASDAQ: TSLA) sales in China, the world’s largest electric vehicle market, may fizzle out by 2030, Morgan Stanley (NYSE: MS) analyst Adam Jonas said in an interview with Yahoo Finance.What Happened: The Elon Musk-led company may see its sales drop to zero by the end of next decade, Jonas told Yahoo Finance.”We have China sales peaking [in the] middle of the decade and then going down…and then eventually nothing after 2030,” the analyst said.”Tesla and other OEMs will have to find a solution outside of China because they won’t be able to compete in the way they are today.”The analyst theorized that the fall in sales in China would be due to future autonomous vehicle systems and the fragile relationship between the United States and China.He said just as it was inconceivable that a Chinese internet of cars autonomous network would be allowed to operate in Boston, similarly, the idea a U.S. vehicle network could be placed in China was a “fallacy.”Why It Matters: Chinese EV manufacturers are already downplaying the impact of Tesla in the domestic market.Baidu Inc (NASDAQ: BIDU)-backed WM Motor Co’s CEO Freeman Shen likened the Palo Alto EV maker to Apple Inc (NASDAQ: AAPL) saying “[They] educate the whole market.”Shen pointed out however that Apple’s market share has been eroded by local players such as Xiaomi Corporation (OTC: XIACF) and Oppo and a similar fate awaits Tesla in the coming decade, Bloomberg reported.Even Tesla’s ,000 vehicle to be released in three years’ time is not a concern for Chinese manufacturers. Xpeng Inc (NASDAQ: XPEV) Vice Chairman Brian Gu said his company’s mid-range vehicles are already at that price point, as per Bloomberg. Homegrown EV firms are seeing robust demand as Warren Buffett-backed BYD Auto Co. Ltd, a unit of BYD Company Limited (OTC: I WILL) said orders for its newly launched “Han” range of vehicles exceeded 40,000 units in just two months of launch since July. Price Action: Tesla shares closed nearly 4.5% higher at $448.16 on Thursday and fell 1.2% to $442.80 in the after-hours session.Latest Ratings for TSLA DateFirmActionFromTo Sep 2020BairdMaintainsNeutral Sep 2020Canaccord GenuityMaintainsHold Sep 2020Deutsche BankUpgradesHoldBuy View More Analyst Ratings for TSLA View the Latest Analyst Ratings See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Tesla Slashes China-Made Standard, Long Range Model 3 Prices * Medtronic Faces Federal Probe Over Causing Ventilator Shortage During Pandemic: WSJ(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
President Trump’s announcement that he has tested positive for the corona virus has grabbed headlines, but the dog that didn’t bark presents a more interesting point. Wall Street isn’t so worried about corona virus anymore; the perception is, that the virus will fade away or a vaccine will be developed, but in either case, the economy will improve.According to an RBC survey of portfolio managers, however, the coming November election presents a clear risk to the markets. A large majority of investors surveyed, 76%, worry that the election will be contested, resulting in weeks – possibly months – on uncertainty. And uncertainty is bad for the markets.Recent events, and some not-to-distant history, bear them out. For the history, we must only look back to 2000, when it took until December 12, and an appeal to the Supreme Court, to decide the results of the Florida recount. The S&P 500 slipped 5% during those weeks – and that was uncertainty caused by one state, recounting a limited number of votes. The point here is not that this election will be fraudulent or illegitimate. Rather, like Caesar’s wife, the election should be above the perception of impropriety – and this year, that bar may be too high. And then the challenges will begin. In the RBC survey, 83% of portfolio managers believed that such challenges, contesting the election results (from either direction) would be a net negative for the stock market. And only a small minority, 14%, believe that the final results will be known when the polls close on Election Day, November 3.And this is what brings us to dividend stocks today. When investors get nervous, they go looking for a way to protect their portfolios – and dividends, making the promise of a steady income stream, may be just the answer skittish shareholders are looking for.Analysts from research firm Compass Point agree. They have picked three stocks whose dividends are yielding 7% or more. We’ve pulled up the TipRanks data to find out what else makes these compelling buys in turbulent times.Saratoga Investment Corporation (SAR)We’ll start with Saratoga Investment Corporation, a mid-market investment management company that specializes in debt, appreciation, and equity investments. Saratoga has over $480 million in assets under management, and its portfolio includes home security, industry, software, and waste disposal. The variety, and the stocks chosen, are designed to give the company a resilient income stream.That doesn’t mean that Saratoga has been able to dodge the corona bullet. The company saw revenues turn negative in Q2, and has seen EPS slip from 61 cents in the first quarter to 51 cents in the second. As a result, Saratoga announced that it was deferring its fiscal Q4 dividend, as a cash-saving measure during the pandemic crisis.Saratoga, in July, declared its fiscal Q1 dividend for 40 cents per common share – and paid it out in August. There are grounds for confidence. The company has $9 million in committed, but undrawn, lending available, along with $155 million in available credit facilities, a new $43.1 million baby bond issue, and $282 million equity – all set against just $60 million in long-term debt.As for the restored dividend, while down 28% from the company’s last dividend payment, the new distribution reflects Saratoga’s liquidity position. The current payment annualizes to $1.60, and gives a yield of 9.2%, or more than 4.5x the average yield found among S&P-listed companies.Covering the stock for Compass Point, analyst Casey Alexander writes of the new dividend, “[With] the dividend now officially reset at $0.40 per quarter, it’s time to make lemonade from the lemons investors were handed… In our view, while we may not be done with credit issues, SAR has set the dividend at a level that allows the BDC to return to the pattern of QoQ dividend increases as the current earnings power of the BDC well exceeds the level of the new dividend.”Taking everything into account, Alexander rates SAR stock a Buy, and gives it a $19.75 price target implying an upside of 16% for the coming year. (To watch Alexander’s track record, click here)Overall, Saratoga gets a unanimous Strong Buy rating from the analyst consensus, based on 3 recent positive reviews. The shares are selling for $17.02 and have an average price target of $22.58, slightly more bullish than Alexander’s and suggesting a one-year upside of ~33%. (See SAR stock analysis on TipRanks)Solar Capital, Ltd. (SLRC)The next stock on our list, Solar Capital, is an investor in senior secured loans and subordinated debt, with an investment portfolio of middle-market companies. The company puts capital into investment-grade loan instruments, making additional financing available to its customer base. Solar Capital has a portfolio worth $1.4 billion invested in 183 companies across 80 business sectors.Solar Capital has been able to keep earnings positive during the ‘corona half,’ despite a sharp fall in the bottom line for Q1 and Q2. In a bright spot, revenues, which turned negative in Q1, were back to positive in Q2, and projections for Q3 earnings show that the fall-off is either slowing or stopping – we will find out which in the Q3 report on November 5.Through all of this uncertainty, Solar Capital has kept up its stable dividend. The company has a 7-year history of reliable dividend payments, and the current quarterly dividend of 41 cents has been paid out consistently for the last 11 quarters. At an annualized payment of $1.64, the dividend currently yields 10.5%. In a time of near-zero official interest rate policy, this gives SLRC an enviable return.Compass Point’s Casey Alexander, who also covers SAR, points out that SLRC’s dividend is the main attraction for investors – and that management has cultivated it for just that purpose. “Management stated their intention to continue to pay the $0.41 per share dividend because they believe there is visibility to dividend coverage as they begin to originate new assets at higher spreads. This is the environment that SLRC has been waiting for, and has been the principal reason for maintaining an under-leveraged posture for the last several years,” Alexander noted.With dividend coverage visible ahead, Alexander gives SLRC a Buy rating. His price target, at $17.75, indicates confidence in a 12% upside potential.This is another stock with a unanimous Strong Buy consensus rating. SLRC is sitting pretty with 5 positive reviews on record. The average price target is $18.20, representing a ~15% upside from the current share price of $15.86. (See SLRC stock analysis on TipRanks)First Hawaiian (FHB)Our last stock today, First Hawaiian, is the holding company owning the First Hawaiian Bank. First Hawaiian offers the usual array of banking services to retail and commercial customers, with 53 branches throughout the Hawaiian Islands along with three others in Guam and two on Saipan. Banking services include loans, deposit accounts, credit and debit cards, mortgages, insurance, and retirement plans.The recently ended second-quarter showed some mixed results. Top line revenues showed a sequential slip, from $164 million to $152 million, but that was mild compared to the 46% drop in earnings. EPS for Q2 came in at 16 cents, on $20 million in net income. Bright spots for the quarter were total loans, which grew 3% to $383 million, and deposit balances, which increased 13% sequentially to reach $2.3 billion. The bank’s total assets at the end of 2Q20 were $23 billion, up 10% from the end of the first quarter.That is the background behind management’s July dividend declaration. The company Board approved a 26-cent regular quarterly dividend, which was paid out in early September. At $1.04 annualized, this dividend yields 7.2%, putting it well above the average yield – and far higher than the current yield on Treasury bonds. FHB has a 4-year history of reliable dividend payments, and the current declaration marks the seventh quarter in a row at the current level.Compass Point analyst Laurie Havener Hunsicker believes a macro look at FHB justifies a bullish stance. “FHB was a clear outperformer on credit during the last crisis. While past results do not dictate future performance, we are impressed with the FHB management team and their credit culture; further, we believe that FHB is well-postured to again outperform on credit during the COVID-19 crisis,” the analyst noted.In line with her comments, Hunsicker rates FHB a Buy and sets a $21 price target that suggests room for a robust share appreciation of 46% over the next year. (To watch Hunsicker’s track record, click here)However, Wall Street is unsure on FHB, and the analysts are evenly divided, with recent reviews coming in at 1 Buy, 1 Hold, and 1 Sell – for an analyst consensus rating of Hold. FHB shares are selling for $14.42 and have an average price target of $16.67, making the upside potential 15%. (See First Hawaiian’s stock analysis at TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The current Medicare Plan G rates may surprise most Americans. Look for the right Medicare supplement plan for you!
Devin McDermott, head of North American oil and gas research at Morgan Stanley, favors Chevron and an assortment of companies that typically focus on infrastructure such as pipelines to transport oil and gas including Magellan Midstream Partners and Enterprise Products Partners.
Tesla, the stock market’s most valuable car company, sold 139,300 cars in the third quarter. But conditions suggest it needs to be selling much more.
Nio and fellow Chinese electric-vehicle maker Li Auto grew September and Q3 sales sharply as SUVs remain hot.
The company slightly beat consensus estimates by Refinitiv for deliveries of 134,720 vehicles, but fell short of some of Wall Street’s most bullish forecasts, with analysts issuing a wide range of estimates. While the broader market was down on Friday morning, Tesla shares were among the heaviest decliners. Tesla delivered 124,100 Model Y and Model 3 units, slightly below Refinitiv consensus expectations of 128,000 Model 3 and Model Y vehicles combined.
Since 2019, the healthcare sector has been bracing for the wild ride that would be the election year. However, according to some Street pros, 2021 is looking a lot like 2009, and this could actually be a good thing for the space.“[We] think 2021 will play out very similarly to 2009 for the health care sector. If in fact the political prediction markets are correct and Democrats seize control of the presidency and the U.S. Senate, the rhetoric on changes to health care policy exceeds the reality of what can be accomplished,” UBS healthcare strategist Eric Potoker noted.Potoker points out that the 2009 passage of the Affordable Care Act (ACA) had a muted effect on the industry, with demand for products and services rising due to expanded health coverage. Healthcare stocks reaped the benefits of this between 2009 and 2015, and the space outperformed the rest of the market.To this end, Potoker believes 2021 will play out in a very similar way, and therefore, is pointing to the healthcare space as a must-watch area of the market.Using TipRanks’ database, we scanned the Street for compelling yet affordable plays within the healthcare sector. Locking in on three trading for less than $5 per share, the platform revealed that even with the risk involved, all three have scored overwhelmingly bullish analyst support, enough to earn a “Strong Buy” consensus rating. What’s more, each boasts a massive upside potential.Kintara Therapeutics (KTRA)Working to meet the needs of patients who are failing or resistant to current treatment regimens, Kintara Therapeutics focuses on developing cutting-edge cancer therapies. Based on its diverse oncology-focused pipeline and $1.40 share price, some members of the Street believe the share price reflects an attractive entry point.Aegis analyst Nathan Weinstein cites the company’s two differentiated, late-stage oncology assets as the primary components of his bullish thesis. These candidates are VAL-083, a small molecule chemotherapeutic agent for the treatment of glioblastoma multiforme (GBM), a highly lethal brain cancer with a 95% five-year mortality rate, and REM-001, a phototherapy designed for the treatment of cutaneous metastatic breast cancer (CMBC).Looking at the former, Weinstein highlights the fact that VAL-083 affects DNA in a different way than the current standard of care, temozolomide (TMZ). “We think VAL-083 could show relative benefit, particularly in MGMT-unmethylated patients. Two thirds of GBM patients have an unmethylated MGMT promoter,” the analyst noted.The MGMT repair enzyme has been found to correct the damage to DNA caused by TMZ. However, patients with an unmethylated MGMT repair enzyme have a poor response to TMZ treatment, which bodes well for KTRA as its therapy has a different mechanism of action. “In our view, data from the ongoing Phase 2 trials presented at AACR (June 2020) are encouraging regarding overall survival (THE) and progression free survival (PFS) data vs historical controls,” Weinstein opined.As for REM-001, it has been evaluated in over 1,000 patients to-date, and thus has a “well-characterized safety profile,” in Weinstein’s opinion. Additionally, in previous CMBC trials, the asset has demonstrated robust efficacy, including 80% complete response of evaluable lesions.All of the above prompted Weinstein to comment, “We find the valuation of Kintara in the market to be compelling, as little value is being ascribed to the company, despite having two phase 3 ready oncology assets with sufficient funding in-place to reach multiple milestones ahead.”To this end, Weinstein rates KTRA a Buy along with a $6 price target. This target conveys his confidence in KTRA’s ability to climb 341% higher in the next year. (To watch Weinstein’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 3 to be exact, have been issued in the last three months. Therefore, the word on the Street is that KTRA is a Strong Buy. Given the $4.33 average price target, shares could soar 218% from current levels. (See KTRA stock analysis on TipRanks)DiaMedica Therapeutics (DMAC)Utilizing its cutting-edge technologies, DiaMedica Therapeutics develops novel recombinant proteins to treat kidney and neurological diseases. With a price tag of $4.20 per share and potential catalysts coming up, it’s no wonder this stock is on Wall Street’s radar.Representing Craig-Hallum, analyst Alexander Nowak sees multiple value-creating catalysts on tap, noting that the company appears “chronically undervalued.” Looking ahead to Q4, DMAC will have a meeting with the FDA for DM199 in acute ischemic stroke (AIS), where break-through designation, Special Protocol Assessment (SPA), Phase 3 trial design and a Phase 3 study greenlight will be topics of discussion. DM199, DMAC’s lead candidate, is a recombinant form of the KLK1 protein (an endogenous serine protease produced in the kidneys, pancreas and salivary glands).According to Nowak, this Phase 3 study is the next major potential catalyst and could possibly lead to strategic partnership conversations. He added, “We also think a SPA that confirms exclusion of mechanical thrombectomy and large vessel occlusion and mRS/NIHSS Excellent Outcome endpoints is a big win (basically means replicate the Phase 2 study in the intent to treat population).”While the meeting will take place later than Nowak thought (he originally expected an August meeting), the delay is due to hiring an external consulting group to help with FDA communication, a “valid and sensible reason for the pushback,” in his opinion.On top of this, DM199 is being evaluated in chronic kidney disease (CKD). The Phase 2 trial enrollment was temporarily paused in Q2, but enrollment has been trending better. It should be noted that the delays have mostly been related to patients that were nervous about coming into the clinic for the initial setup during the COVID crisis. Bearing this in mind, the analyst expects the data readout to come in Q1 2021. Summing it all up, Nowak stated, “We still view the Phase 2 CKD trial as the more significant, immediate value-creating opportunity, given the large market and recent industry successes (RETA). But we are more bullish than most investors on stroke too, as the only drug used is more than two decades old, no serious competitors are in the pipeline and approval (which could be done in only a few hundred patients) could lead to a very rapid uptake within 1-2 years.”Everything that DMAC has going for it convinced Nowak to reiterate his Buy rating. Along with the call, he attached a $15 price target, suggesting 265% upside potential. (To watch Nowak’s track record, click here)Overall, DMAC shares get a unanimous thumbs up from the analyst consensus, with 3 recent Buy reviews adding up to a Strong Buy rating. At $14.33, the average price target implies 248% upside potential from current levels. (See DMAC stock analysis on TipRanks)OPKO Health (OPK)Through its unique products, comprehensive diagnostics laboratories and robust research and development pipeline, OPKO Health wants to improve the lives of patients. OPKO shares have surged 162% this year, but at $3.86 apiece, several analysts believe this stock is still undervalued.Following the announcement that OPK had kicked off the Phase 2 REsCue study of Rayaldee for the treatment of mild-to-moderate COVID-19, 5-star analyst Edward Tenthoff, of Piper Sandler, points out that he has high hopes for the company. Rayaldee is currently approved for secondary hyperparathyroidism (SHPT) in stage 3-4 Chronic Kidney Disease (CKD), and is progressing through a Phase 2 study in dialysis patients.According to Tenthoff, many of the patients in the COVID study will have stage 3-4 CKD, “where Rayaldee has demonstrated clinical benefit.” On top of this, the analyst thinks boosting serum 25D may augment macrophage immunity by secreting potent antiviral proteins targeting.Reflecting another positive, service revenue of $251 million in Q2 2020 beat expectations as a result of the 2.2 million SARS-CoV-2 PCR and antibody tests performed at BioReference Labs in the quarter. Adding to the good news, OPK guided for 45,000-55,000 tests per day in Q3 2020 and service revenue of $325-350 million in the quarter. It should be noted that this includes the base diagnostic business, which is starting to bounce back. To this end, Tenthoff estimates service revenue could climb 53% higher to reach $1.1 billion this year.Tenthoff is also looking forward to the somatrogon, the company’s treatment for pediatric growth hormone deficiency (GHD), regulatory filings. Its partner, Pfizer, plans to submit the BLA this fall, with U.S. approval and market launch potentially coming in 2H21. An open-label European study is expected to wrap up this quarter, and will enable an EMA filing in 2021. In addition, pivotal Phase 3 Japanese data in pediatric GHD patients could support a regulatory filing in the country in 1H21.Based on the therapy’s Phase 3 trial, in which it met the primary endpoint with height velocity, Tenthoff sees approval as being likely.In line with his optimistic approach, Tenthoff stays with the bulls. To this end, he keeps an Overweight (i.e Buy) rating and $10 price target on the stock. Investors could be pocketing a gain of 159%, should this target be met in the twelve months ahead. (To watch Tenthoff’s track record, click here)All in all, other analysts echo Tenthoff’s sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $8, the upside potential comes in at 107%. (See OPKO stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
How badly is COVID-19 hurting Americans on the cusp of retirement? In an interview, economist Teresa Ghilarducci, a professor at The New School in New York City and one of the nation’s leading experts on retirement, told me that half—that’s right, half—of Americans aged 55 and up will retire in poverty or near poverty. 80% of older Americans can’t afford to retire – COVID-19 isn’t helping More than 25 million older Americans are financially insecure – living at or below the federal poverty level.
(Bloomberg) — Tesla Inc. delivered a record number of cars worldwide in the third quarter, smashing analysts’ estimates and maintaining its dominance in electric-vehicle sales — making a difficult year-end sales goal slightly more attainable.The Palo Alto, California-based carmaker delivered 139,300 cars, eclipsing its prior all-time high of 112,000 in the fourth quarter of 2019 and above the 129,950 projected by analysts surveyed by Bloomberg.Shares of Tesla, which have rallied more than five-fold this year, pared a decline of as much as 6.8% to trade down 3.3% to $433.17 as of 9:59 a.m. in New York. That was part of a broad selloff of stocks after President Donald Trump disclosed a positive test for Covid-19.“Overall, these are stellar numbers,” Dan Ives, an analyst at Wedbush, said in a phone interview early Friday. “The read through here is that China was a source of strength.”Ambitious TargetTesla didn’t say whether it still expects to deliver at least 500,000 vehicles this year, which would be a 36% gain over 2019. The company has handed over 318,350 cars to customers as of Sept. 30. It will need a blowout fourth quarter of around 181,650 global deliveries to reach its target.Tesla may find it challenging to ramp production in the fourth quarter to the level needed to hit 500,000 vehicles for the year, Dan Levy, an analyst at Credit Suisse who has an equivalent of a neutral rating on the stock, said in a research note to clients.At the company’s ‘Battery Day’ event last month showcasing its technology, Musk reaffirmed that 500,000 goal for 2020 by saying he expected “somewhere between 30-40% growth” compared with last year.What Bloomberg Intelligence Says:“Tesla’s record deliveries in 3Q — 139,300 globally — followed by a similar number in 4Q buys the company a pass if it misses the 500,000-unit target for the full year. Hitting the goal would require 181,000 deliveries in 4Q, a quarterly production level — 145,000 was a record in 3Q — that will be difficult to achieve in the next 13 weeks.”– Kevin Tynan, senior autos analystClick here to read the researchThe strong showing by Tesla remains a bright spot in a global auto industry roiled by the pandemic. The quarterly sales are a barometer of worldwide EV demand as Tesla seeks to maintain its lead over startups and established automakers alike that plan to launch dozens of competing battery-powered vehicles in the next several years. Tesla’s global market share in EVs last year was an industry-leading 16%, according to a recent report by McKinsey & Co.Chief Executive Officer Elon Musk signaled to employees and investors that a record quarter was within reach in an internal email in late September.Read more: Musk Says Tesla Has ‘Shot at Record Quarter’ in Staff EmailSlimmer StockpileTesla said its stockpile of vehicles shrank in the latest quarter, crediting smoother logistics in getting cars to customers. “New vehicle inventory declined further in Q3 as we continue to improve our delivery efficiency,” it said in a statement.Tesla’s mass-market Model 3 made up the bulk of deliveries in the third quarter, but the results included the Model Y crossover, which first started reaching U.S. customers in mid-March. Musk has predicted it will be a big seller, potentially topping the combined volume of all other vehicles in Tesla’s lineup.Deliveries of Tesla’s older and more expensive S and X models declined 13% to 15,200 vehicles in the quarter compared to a year ago.Tesla assembles the Model S, X, 3 and Y at its U.S. auto plant in Fremont, California. It also manufactures the Model 3 at a factory in Shanghai. The company is building new plants at a site near Austin, Texas, and outside Berlin.Tesla does not break down production or sales by region, making it hard to know how many cars the Shanghai plant, where Tesla currently makes the Model 3, cranked out. The U.S. and China have long been Tesla’s strongest markets.(An earlier version of this story included a photo with an incorrect caption.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
(Bloomberg) — An industry group representing Walt Disney Co. and other theme-park operators lashed out at new guidance from California, which would only allow attractions like Disneyland to reopen under strict conditions.The organization called for changes to the rules, which haven’t been formally released yet but began to surface on Thursday. Parks would be allowed to reopen at just 25% of capacity and would have to limit visitors to people living within a certain distance, according to Carlye Wisel, an industry podcaster. They’ll also require advance reservations and mandatory face coverings.In a sign of the tensions between Disney and California, Chairman Bob Iger has resigned from the governor’s Covid-19 recovery task force, the company confirmed on Thursday. The Sacramento Bee previously reported his exit.“While we are aligned on many of the protocols and health and safety requirements, there are many others that need to be modified if they are to lead to a responsible and reasonable amusement park reopening plan,” the industry group, the California Attractions & Parks Association, said in an emailed statement.A spokesman for the health department said the rules are coming this week but couldn’t confirm the details.The protocols are one step in the approval process for parks to reopen. Counties where the properties are located will also have to meet milestones for progress in the fight against Covid-19.Disney and other theme-park operations, such as Comcast Corp.’s Universal Studios and SeaWorld Entertainment Inc., have been pressing Governor Gavin Newsom to let them reopen. Earlier this week, 19 state legislators wrote a letter to the governor, a Democrat, saying the time had come.Theme parks in Florida, the largest market, began reopening in June and have done so without large outbreaks, according to officials in that state.Disney, based in Burbank, California, said this week it is laying off 28,000 U.S. workers in its domestic resorts operation — roughly a quarter of the workforce in that division.(Updates with Disney statement in third paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Dividends alone can’t offset declines. While many of the largest technology stocks have done quite well — like Amazon.com (ticker: AMZN), which has surged more than 60% this year — stocks in other sectors have had it much worse. Disruptions caused by the pandemic have changed the game, however, and while the following seven dividend stocks are still paying out distributions of some kind, they remain very much in danger — as they are among the dividend stocks that have dropped the most this year.
Google Nest, Smart speaker, Xiaomi, Amazon Echo, Loudspeaker, Home automation
World news – THAT – Smart Speaker Market Peps Up: GOOGL, AMZN & Others to Watch